Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia.
Identifieur interne : 003B83 ( PubMed/Corpus ); précédent : 003B82; suivant : 003B84Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia.
Auteurs : Charles H. Adler ; Stewart A. Factor ; Mitchell Brin ; Kapil D. SethiSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2002.
English descriptors
- KwdEn :
- Adult, Aged, Botulinum Toxins, Type A (administration & dosage), Botulinum Toxins, Type A (therapeutic use), Drug Resistance, Dystonia (diagnosis), Dystonia (drug therapy), Female, Humans, Injections, Intramuscular, Male, Mandibular Diseases (diagnosis), Mandibular Diseases (drug therapy), Middle Aged, Neuromuscular Agents (administration & dosage), Neuromuscular Agents (therapeutic use).
- MESH :
- chemical , administration & dosage : Botulinum Toxins, Type A, Neuromuscular Agents.
- chemical , therapeutic use : Botulinum Toxins, Type A, Neuromuscular Agents.
- diagnosis : Dystonia, Mandibular Diseases.
- drug therapy : Dystonia, Mandibular Diseases.
- Adult, Aged, Drug Resistance, Female, Humans, Injections, Intramuscular, Male, Middle Aged.
Abstract
Intramuscular injection of botulinum toxin type A is the treatment of choice for most cases of oromandibular dystonia. We report on five patients with oromandibular dystonia that developed secondary nonresponsiveness to botulinum toxin type A following multiple injections over a 6-year period.
PubMed: 11835455
Links to Exploration step
pubmed:11835455Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia.</title>
<author><name sortKey="Adler, Charles H" sort="Adler, Charles H" uniqKey="Adler C" first="Charles H" last="Adler">Charles H. Adler</name>
<affiliation><nlm:affiliation>Parkinson's Disease and Movement Disorders Center, Mayo Clinic Scottsdale, Scottsdale, Arizona, USA. cadler@mayo.edu</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Factor, Stewart A" sort="Factor, Stewart A" uniqKey="Factor S" first="Stewart A" last="Factor">Stewart A. Factor</name>
</author>
<author><name sortKey="Brin, Mitchell" sort="Brin, Mitchell" uniqKey="Brin M" first="Mitchell" last="Brin">Mitchell Brin</name>
</author>
<author><name sortKey="Sethi, Kapil D" sort="Sethi, Kapil D" uniqKey="Sethi K" first="Kapil D" last="Sethi">Kapil D. Sethi</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2002">2002</date>
<idno type="RBID">pubmed:11835455</idno>
<idno type="pmid">11835455</idno>
<idno type="wicri:Area/PubMed/Corpus">003B83</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia.</title>
<author><name sortKey="Adler, Charles H" sort="Adler, Charles H" uniqKey="Adler C" first="Charles H" last="Adler">Charles H. Adler</name>
<affiliation><nlm:affiliation>Parkinson's Disease and Movement Disorders Center, Mayo Clinic Scottsdale, Scottsdale, Arizona, USA. cadler@mayo.edu</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Factor, Stewart A" sort="Factor, Stewart A" uniqKey="Factor S" first="Stewart A" last="Factor">Stewart A. Factor</name>
</author>
<author><name sortKey="Brin, Mitchell" sort="Brin, Mitchell" uniqKey="Brin M" first="Mitchell" last="Brin">Mitchell Brin</name>
</author>
<author><name sortKey="Sethi, Kapil D" sort="Sethi, Kapil D" uniqKey="Sethi K" first="Kapil D" last="Sethi">Kapil D. Sethi</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2002" type="published">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Botulinum Toxins, Type A (administration & dosage)</term>
<term>Botulinum Toxins, Type A (therapeutic use)</term>
<term>Drug Resistance</term>
<term>Dystonia (diagnosis)</term>
<term>Dystonia (drug therapy)</term>
<term>Female</term>
<term>Humans</term>
<term>Injections, Intramuscular</term>
<term>Male</term>
<term>Mandibular Diseases (diagnosis)</term>
<term>Mandibular Diseases (drug therapy)</term>
<term>Middle Aged</term>
<term>Neuromuscular Agents (administration & dosage)</term>
<term>Neuromuscular Agents (therapeutic use)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Botulinum Toxins, Type A</term>
<term>Neuromuscular Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Botulinum Toxins, Type A</term>
<term>Neuromuscular Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Dystonia</term>
<term>Mandibular Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dystonia</term>
<term>Mandibular Diseases</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Drug Resistance</term>
<term>Female</term>
<term>Humans</term>
<term>Injections, Intramuscular</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Intramuscular injection of botulinum toxin type A is the treatment of choice for most cases of oromandibular dystonia. We report on five patients with oromandibular dystonia that developed secondary nonresponsiveness to botulinum toxin type A following multiple injections over a 6-year period.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">11835455</PMID>
<DateCreated><Year>2002</Year>
<Month>02</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted><Year>2002</Year>
<Month>05</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised><Year>2010</Year>
<Month>11</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN>
<JournalIssue CitedMedium="Print"><Volume>17</Volume>
<Issue>1</Issue>
<PubDate><Year>2002</Year>
<Month>Jan</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia.</ArticleTitle>
<Pagination><MedlinePgn>158-61</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Intramuscular injection of botulinum toxin type A is the treatment of choice for most cases of oromandibular dystonia. We report on five patients with oromandibular dystonia that developed secondary nonresponsiveness to botulinum toxin type A following multiple injections over a 6-year period.</AbstractText>
<CopyrightInformation>Copyright 2002 Movement Disorder Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Adler</LastName>
<ForeName>Charles H</ForeName>
<Initials>CH</Initials>
<AffiliationInfo><Affiliation>Parkinson's Disease and Movement Disorders Center, Mayo Clinic Scottsdale, Scottsdale, Arizona, USA. cadler@mayo.edu</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Factor</LastName>
<ForeName>Stewart A</ForeName>
<Initials>SA</Initials>
</Author>
<Author ValidYN="Y"><LastName>Brin</LastName>
<ForeName>Mitchell</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Sethi</LastName>
<ForeName>Kapil D</ForeName>
<Initials>KD</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009465">Neuromuscular Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.24.69</RegistryNumber>
<NameOfSubstance UI="D019274">Botulinum Toxins, Type A</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D019274">Botulinum Toxins, Type A</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004351">Drug Resistance</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004421">Dystonia</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D007273">Injections, Intramuscular</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008336">Mandibular Diseases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D009465">Neuromuscular Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year>
<Month>2</Month>
<Day>9</Day>
<Hour>10</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2002</Year>
<Month>5</Month>
<Day>25</Day>
<Hour>10</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2002</Year>
<Month>2</Month>
<Day>9</Day>
<Hour>10</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">11835455</ArticleId>
<ArticleId IdType="pii">10.1002/mds.10001</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003B83 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003B83 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:11835455 |texte= Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:11835455" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
![]() | This area was generated with Dilib version V0.6.23. | ![]() |